The article has been automatically translated into English by Google Translate from Russian and has not been edited.
Переклад цього матеріалу українською мовою з російської було автоматично здійснено сервісом Google Translate, без подальшого редагування тексту.
Bu məqalə Google Translate servisi vasitəsi ilə avtomatik olaraq rus dilindən azərbaycan dilinə tərcümə olunmuşdur. Bundan sonra mətn redaktə edilməmişdir.

FDA approves emergency treatment for COVID-19 with new combination of drugs

The US Food and Drug Administration (FDA) on Thursday, November 19, issued an emergency authorization for the combination drug for the treatment of patients with moderate to severe COVID-19 disease. Fox News.

Photo: Shutterstock

A combination regimen combining the rheumatoid arthritis drug baricitinib and remdesivir (both from Gilead) has been approved for the treatment of hospitalized patients 2 years of age or older who require oxygen. The FDA said the drugs shorten the patient's recovery time. These findings were made in a study sponsored by the National Institute of Allergy and Infectious Diseases, called the Adaptive COVID-19 Treatment Trial (ACTT-2).

Among the 1033 coronavirus patients in the study with at least a mild course of illness, the patients who took this combination of drugs recovered after 7 days, while the other group (placebo plus remdesivir) took eight days.

"The likelihood of patient progression to death or mechanical ventilation on day 29 was lower in the baricitinib-remdesivir group compared to the placebo-remdesivir group," the FDA said in a statement.

On the subject: FDA approves emergency treatment for COVID-19 with antibodies: what is this method

“The safety and efficacy of this research therapy for the treatment of COVID-19 continues to be evaluated,” the statement said.

Baricitinib, marketed under the brand name Olumiant, inhibits the process that leads to inflammation.

"The FDA's emergency clearance for this combination therapy represents a gradual step forward in the treatment of COVID-19 in hospitalized patients, as well as the first FDA approval for a drug that works against inflammation," said Dr. Patricia Cavazzoni, acting FDA director. “Despite advances in managing COVID-19 infection since the start of the pandemic, we need more treatments to accelerate recovery, and more clinical research will be needed to identify treatments that slow disease progression and reduce mortality in severely ill patients.”

Meanwhile, Gilead's remdesivir has already received FDA approval as the first treatment for COVID-19 for patients over 12 years old. This approval follows the results of a study published in the New England Journal of Medicine, which showed faster recovery times than before. Treatment has been reported for adults hospitalized with mild, moderate, or severe COVID-19. Remdesivir also reduces the progression of the disease in critically ill patients requiring oxygen.

You may be interested in: top New York news, stories of our immigrants and helpful tips about life in the Big Apple - чread it all on ForumDaily New York

However, on Friday, November 20, a WHO expert group advised against the use of remdesivir for hospitalized coronavirus patients, citing "little or no effect" in patients after international trials. Gilead disputed these claims.

Miscellaneous In the U.S. coronavirus Special Projects Mesures COVID-19

Read also on ForumDaily:

Nearly 95%: Another company says its COVID-19 vaccine is effective

Tens of millions of people a month: how Americans will be vaccinated against COVID-19

Pre-travel coronavirus test: when, where and how to do it

A negative test does not guarantee that you do not have COVID-19: how to know for sure

Do you want more important and interesting news about life in the USA and immigration to America? Subscribe to our page in Facebook. Choose the "Display Priority" option and read us first. And don't forget to subscribe to ForumDaily Woman and ForumDaily New York - there you will find a lot of interesting and positive information. 

1063 requests in 2,610 seconds.